Lessons learned from the real-world diagnosis and management of hereditary hypophosphatemic rickets

• Published in: Bone Reports 2024-06, Vol.21, p.101753, Article 101753
• Main Authors: Chaturvedi, Deepti, Mehasi, Taif EmadEldin, Benbrahim, Assia, ElDeeb, Lubna, Deeb, Asma
• Format: Article
• Language: English
• Subjects: Autosomal recessive hypophosphatemic rickets; Burosumab; DMP1; Full Length; PHEX; Phosphate; X-linked hypophosphatemia
• ISSN: 2352-1872; 2352-1872
• DOI: 10.1016/j.bonr.2024.101753

Hypophosphatemic rickets, which is often hereditary, is still under- or misdiagnosed in both children and adults, denying these individuals access to optimal management and genetic counseling. There have been recent calls to compile real-world data and share best practice on these rare conditions to guide clinical decision-making. Here we present eight clinical vignettes of patients with hypophosphatemic rickets encountered in our tertiary pediatric endocrinology practice. We describe the clinical features, genetics, and management of four cases of X-linked hypophosphatemia (PHEX mutations), one each of autosomal recessive hypophosphatemic rickets (DMP1 mutation) and autosomal recessive vitamin D-dependent rickets type 1A (CYP27B1 mutation), and two cases of distal renal tubular acidosis with FOXI1 mutation-associated hypophosphatemic rickets. Our cases prompt consideration of the (i) frequent misdiagnosis of hypophosphatemic rickets in clinical practice and the importance of comprehensive genetic testing; (ii) variable expressivity of the causative mutations; and (iii) a lack of responsiveness and/or compliance to conventional therapy and the value of burosumab in modern management, provided access is equitable. These cases highlight common real-world themes and challenges to managing patients presenting with these diverse conditions, especially the burden of disease hidden by misdiagnosis. In sharing these cases, we hope to raise awareness of these conditions, promote best practice in genetic diagnosis and management, and further advocate for reimbursement equity for the best available therapies.